Dutch enforcer closes abuse probe into Pfizer

Pfizer has agreed to stop its exclusivity-based discount system for the provision of a drug supplied to hospitals for treating autoimmune diseases in order to end an abuse of dominance investigation by the Dutch competition authority.

Get unlimited access to all Global Competition Review content